ࡱ> wyvg #bjbj** AdHibHib3  """"""""8"l@#"tND##($$$8%<t&d&4MMMMMMM$PnSN"<(8%8%<(<(N""$$4.Nv.v.v.<(X"$"$Mv.<(Mv.v.@E=J$Ps(}I"MDN0tNIdTR)jT4JT"J '>J',v.v'$' ' ' 'NN, ' ' 'tN<(<(<(<(T ' ' ' ' ' ' ' ' ' B N!: Pre Clinical Trial Agreement This Pre Clinical Trial Agreement (Agreement) is by and between: Parties Central Adelaide LOCAL Health NETWORK (abn 96 269 526 412), of North Terrace, Adelaide SA 5000 (Institution) and XXX (ABN xx) of xxx (Company). Institution and Company, collectively the Parties Recitals The Company wishes to provide the Institution with confidential proprietary information and materials related to a study referred to in Item 1 of the Schedule (Study). In order to evaluate various aspects of the Study and to assess the feasibility of the Institution performing the Study, the Institution will perform certain activities (Activities). The Parties have agreed that the Company will pay the Institution for the conduct of the Activities prior to the commencement of the Study. If the Parties decide to proceed with the Study, the Parties will enter into a separate document (Clinical Trial Research Agreement) concerning the conduct of the Study. The Parties now agree as follows: Term and Termination This Agreement commences the date of the party to sign last and ends at the earlier of the following times: when the Parties enter into a Clinical Trial Research Agreement in relation to the Study; or when the Agreement is terminated in accordance with clause 2. The Company may terminate this Agreement with 30 days prior written notice to the Institution. In the event of such early termination, the Company must pay the Institution in accordance with Item 2 of the Schedule for all Activities performed until the date of termination. Activities The Institution will perform the Activities as set out in Item 3 of the Schedule. Principal Investigator The Institution has authorised the person specified in Item 4 of the Schedule as the person responsible on a day to day basis for the conduct of the Activities (Principal Investigator) Payment In consideration of the Institution performing the Activities, the Company will pay the Institution the amounts and in the manner as set out in Item 2 of the Schedule. The amounts set out in Item 2 of the Schedule do not include GST. At the time of payment, the Company must pay to the Institution any amount of GST that the Institution is required to pay in addition to the prices set out in Item 2 of the Schedule. Any obligation on the Company to pay the Institution under this Agreement: arises whether or not the Company and Institution subsequently enter into a Clinical Trial Research Agreement; and survives termination of this Agreement. Companys Products Neither this Agreement nor any consideration paid under this Agreement is contingent upon the Institutions use or purchase of any of the Companys products. Intellectual Property This Agreement does not affect any Partys right to its respective intellectual property. Neither Party acquires any rights concerning the intellectual property of the other Party. In this Agreement, intellectual property means all and any patents, patent applications, trademarks, service marks, trade names, registered designs, unregistered design rights, copyrights, know-how, trade secrets, domain names, rights in confidential information, and any other intellectual property, whether registered or unregistered and including all applications and rights to apply for any of the same. Confidential Information A Party must not use or disclose any Confidential Information of the other Party for the performance of the Activities except in the following circumstances: where the use or disclosure is necessary for the performance of the Activities; where the use or disclosure relates to an application to the Institutions Human Research and Ethics Committee for approval of the Study; where the Confidential Information has entered the public domain other than as a result of a breach of this Agreement; where release of the Confidential Information is required by law, with notice as soon as reasonably practical to the Company; for the purposes of legal advice; or for the purposes of disclosure to a Partys insurer. In this Agreement, Confidential Information means information in relation to a Partys: business, operations or strategies personnel, consultants and patients; information designated as confidential by a party; information acquired by the other party solely by virtue of the provisions of this agreement; intellectual property or other property; or actual or prospective customers, clients or competitors. Governing Law and Jurisdiction This Agreement is governed by and will be construed in accordance with the laws of South Australia. The parties submit to the non-exclusive jurisdiction of the courts of South Australia and courts entitled to hear appeals from those courts. Miscellaneous Variation of any of the terms of this Agreement must be in writing and signed by both Parties. For the purposes of this agreement, GST, taxable supply and tax invoice have the meanings attributed to those terms in A New Tax System (Goods and Services Tax) Act 1999 (Cwlth). If GST is imposed on any supply made under or in accordance with this agreement, the recipient of the taxable supply must pay to the supplier an amount equal to the GST payable on or for the supply subject to the recipient receiving a valid tax invoice in respect of the supply at or before the time of payment. This Agreement contains the entire understanding between the Parties concerning the subject matter of the Agreement and supersedes all prior communications between the Parties. Any provision of this Agreement which is invalid must: be read down to the minimum extent necessary to achieve its validity, if applicable; and be severed from this Agreement in any other case, without invalidating or affecting the remaining provisions of this Agreement or the validity of that provision. The relationship between the Parties is that of principal and independent contractor. No Party is an agent, representative or partner of any other Party by virtue of this Agreement. In the event of any inconsistency, this Agreement must be interpreted in accordance with the following in order of priority: the special conditions set out in item 5 of the Schedule (if any); and then the terms and conditions set out in the body of this Agreement. Execution Signed on behalf of the Institution Signed: Name: Position: Date: / /  Signed on behalf of the Company Signed: Name: Position: Date: / /  Acknowledged by the Principal Investigator Signed: Name: Position: Date: / /  Schedule Item 1StudyTitle: Protocol: Item 2PaymentManner of payment: Prices: Time of payment: Item 3Activities Item 4Principal Investigator Item 5Special Conditions     CALHN Pre Clinical Trial Agreement -09 December 2015 Page  PAGE 2 of  NUMPAGES 5  "4L^_`ahi0 1 żͱ͙Ņyj_T_Lhr(-CJ^JhR h)[CJ^JhR hr(-CJ^JhR h5B*CJ^JphhUWB*CJ^JphhR hr(-5CJ^Jh7ACJ^JhR hR ;CJ^Jh\shR ;CJaJh\shR CJaJhR hR CJhR CJ^JhR hR CJ^J hR CJ h7ACJhR hr(-CJhEh0vCJ$aJ$h7ACJ$aJ$ai1 : - nnnn&$ & F nڏ0d5$7$8$9DH$^`0a$gd$ $da$gd$$0d^`0a$gd$$a$gd$$0d^`0a$gd$ ) p@ P !$gdR  & F`d^``gd~S 1 : X s * + , - 5 B c ƽƝvgvg[gvh_)5CJ^JnH tH h>`h>`CJ^JnH tH h>`CJ^JnH tH h>`h>`B*CJ^Jph h_)5CJ h>`CJh>`h>`CJ ha5CJh>`ha5CJ haCJhhaCJh}hhaB*CJ^Jphh}hha5CJ^Jh}hhaCJ^Jh}hhaCJhR hr(-CJaJ!    ( ) K |  ŽsgXgXIgIX8 hR h"5B*CJ^JphhR h=B*CJ^JphhR h"B*CJ^Jphh-xRB*CJ^JphhR h.jZB*CJ^JphhR h B*CJ^JphhR h=CJ^JhR hN<CJ^JhR h;vTCJ^JhR hr(-CJaJhR CJaJh>`h>`B*CJ^Jphh>`h>`CJ^JnH tH h>`CJ^JnH tH h>`h>`5CJ^JnH tH   |  *5Ya N$ & F nڏd^`a$gd$$ & F enڏ0d^`0a$gd$$ & F0d5$7$8$9DH$^`0a$gd$$ r 0d^`0a$gd$   f j u w ()*459DIV`oƾƳև|thYMYhB*CJ^JphhR h;vTB*CJ^Jphh~ B*CJ^Jphh?CJ^JhR h;vTCJ^JhR h"B*CJ^JphhCJ^Jh-xR5CJ^JhR hN<5CJ^JhR hN<CJ^Jh-xRCJ^JhR CJ^Jh_)5CJ^JhR h"CJ^JhR h B*CJ^JphhR h=B*CJ^Jphotu3=>BVXYuyŽŭřŐs߽hߙ`h߽h~ CJ^JhR hFCJ^J h_)5h&v5B*CJ^Jphh_)5h&v5CJ^Jh_)55CJ^JhCJ^JhR h&v5CJ^Jh?CJ^JhR CJ^Jh_)5CJ^JhR h&vCJ^JhR h;vTB*CJ^JphhR h;vTCJ^Jh-xR5CJ^JhR h;vT5CJ^J!  %&67FI{(ĸӠӍzzk\hR h7B*CJ^JphhR h;vTB*CJ^JphhR CJ^JhR hCJ^JhR h;vTCJ^Jh?CJ^JhR h ZB*CJ^Jphh-xR5CJ^JhR hF5CJ^JhR hFCJ^JmH sH hR hFCJ^JhR h7T$CJ^Jh7T$CJ^JhR h;vTCJ^JmH sH #(,7LMNtV[e?_efw'Ͷ붔zztznz_Yztztz haCJhahaB*CJ^Jph h}CJ h?CJh?h?CJ h7T$CJhR hFCJ^JhR h ZB*CJ^Jphh?CJ^JhR hCJ^JhR h ZCJ^Jh-xRB*CJ^JphhR hh B*CJ^JphhR h7B*CJ^JphhR CJ^Jh?B*CJ^Jph"Nfii&$ & F enڏ0d5$7$8$9DH$^`0a$gd$$ & F enڏ0d^`0a$gd$$ & F0d5$7$8$9DH$^`0a$gd$$ & F nڏd`a$gd$$ & F nڏ0d^`0a$gd$ '()H=IJh>)嶫~ԫګګ<0CJ^JhR CJ^Jh7T$CJ^JhR h&CJ^JhR h ZCJ^J hR hpCJOJQJ^JaJh<0CJOJQJaJh<0h<0CJOJQJaJ$V}jj&$ & F e0dxx^`0a$gd<0 $ nڏ0d5$7$8$9DH$^`0a$gd$& & F 0dxx^`0gd$& & F e0dxx^`0gd$$ & F0d5$7$8$9DH$^`0a$gd$ !23S{ " \ | 1!J!Q!R!!!!!!"""&"2"@"H"V"W"Ⱥztkgkgkgkgkhh2h^J h7CJh2hCJh7h5CJh2h7ACJhh5CJhhCJhhr(-CJ^JaJh$h$CJOJQJ^JaJh\sCJOJQJ^JaJ h<0h<0CJOJQJ^JaJhC/eCJOJQJ^JaJhF:h<0CJ^J(F N`kd$$Ifl70xJ  t44 lapyt2 $Ifgd2gdgd$&$ & F 0dxx^`0a$gda&$ & F 0dxx^`0a$gd<0 !6`kd$$Ifl70xJ  t44 lapyt2`kdv$$Ifl70xJ  t44 lapyt2 $Ifgd2!0!1!2!R!Z!i! $Ifgdgd`kdb$$Ifl70xJ  t44 lapyt2 $Ifgd2i!j!p!!!!!6`kdN$$Ifl70xJ  t44 lapyt2 $Ifgd`kd$$Ifl70xJ  t44 lapyt2!!!!!!61gd`kd:$$Ifl70xJ  t44 lapyt2 $Ifgd`kd$$Ifl70xJ  t44 lapyt2!!""""'"`kd$$Ifl70xJ  t44 lapyt2 $Ifgd$_gd'"("2"A"B"H"u"6`kd$$Ifl70xJ  t44 lapyt2 $Ifgd$_`kd&$$Ifl70xJ  t44 lapyt2W"e"f"t"v"w"x"""""""""""""""""""""""""""""###/#2#źݧݲݧynynhR hC/eCJ^JhC/eCJ^JhCJ^JhR htCJ^JhR h-xRCJ^Jhr(-CJ^JhR hpCJ^Jh-xRCJ^JhR h2B*CJ^JhR hr(-5CJ^JhR hl5CJ^JhR hr(-CJ^JhR h&vCJ^Jh2h^Jh'u"v"w""""""" d$IfgdaN $da$gdaNgd6i`kd$$Ifl70xJ  t44 lapyt2""""""""""thh\\\\\\ d$Ifgdt d$Ifgdkd$$IflF %p t0    4 layt$ """"""thhhh d$IfgdNPkd$$$IflF %p t0    4 layt$"""###thhhh d$IfgdNPkd$$IflF %p t0    4 layt$###0#1#thhh d$IfgdNPkd\$$IflF %p t0    4 layt$1#2#3#5#6#8#9#;#<#>#?##tkiiiiiiii`gd`gdE kd$$IflF %p t0    4 layt$ 2#3#4#6#7#9#:#<#=#?#X#c#o#s##################ƷƷƷƷƓh: jh`h`CJUaJ*h$CJaJmHnHu*jh`h`CJUaJh`h`CJaJhSCJaJh$CJaJh7ACJaJhyx"jhyx"UhR hrKCJ^J####gdE ?0P1h:p$. A!8"8#$% Dpt$$If!vh#vJ#v :V l7 t5J5 / pyt2t$$If!vh#vJ#v :V l7 t5J5 / pyt2t$$If!vh#vJ#v :V l7 t5J5 / pyt2t$$If!vh#vJ#v :V l7 t5J5 / pyt2t$$If!vh#vJ#v :V l7 t5J5 / pyt2t$$If!vh#vJ#v :V l7 t5J5 / pyt2t$$If!vh#vJ#v :V l7 t5J5 / pyt2t$$If!vh#vJ#v :V l7 t5J5 / pyt2t$$If!vh#vJ#v :V l7 t5J5 / pyt2t$$If!vh#vJ#v :V l7 t5J5 / pyt2t$$If!vh#vJ#v :V l7 t5J5 / pyt2t$$If!vh#vJ#v :V l7 t5J5 / pyt2$$If!vh#v#vp#v:V l t055p54yt$$$If!vh#v#vp#v:V l t055p54yt$$$If!vh#v#vp#v:V l t055p54yt$$$If!vh#v#vp#v:V l t055p5/ 4yt$$$If!vh#v#vp#v:V l t055p5/ 4yt$,s2 0@P`p2( 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p8XV~ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@_HmH nH sH tH L`L Normal xxCJOJQJ_HmH sH tH @ >Heading 1,1,A MAJOR/BOLD,No numbers,Section Heading,h1,Para,H1$ & F@& 5CJ\R@R  Heading 2$<@&5CJ\]^JaJNN  Heading 3$<@&5CJ\^JaJFF  Heading 4$ & F@& 5CJ\jj r(- Heading 5%<5$7$8$9D@&H$^CJOJQJmH sH tH nn r(- Heading 6%<5$7$8$9D@&H$^6CJOJQJmH sH tH jj r(- Heading 7%<5$7$8$9D@&H$^CJOJQJmH sH tH nn r(- Heading 8%<5$7$8$9D@&H$^6CJOJQJmH sH tH n n r(- Heading 9% <5$7$8$9D@&H$^6CJOJQJmH sH tH DA D Default Paragraph FontVi@V  Table Normal :V 44 la (k (No List  Monique's Headingc$d%d&d'd-D1$7$8$H$M NOPQ5mH sH u>>> Title$a$5CJ OJQJ\LCL Body Text Indent0^`0HR"H Body Text Indent 2 ^HS2H Body Text Indent 3 ^4B4 Header  9r 4 @R4 Footer  9r .)a. Page Number.. TOC 2 ^6U 6 Hyperlink >*B*phHH  Balloon TextCJOJQJ^JaJ&& TOC 1.B. r(- Body Textbb Numbered paragraph (lc letters)  & F Rec Number$ & F;dh>T7.Tf^`;a$ CJOJQJ|| PF (Num) Level 28   q E~ "@@@@@@@Bdd^`d B*ph~~ PF Bullet Level 18  8 q E~ "@@@@@@@B8dd^8`d B*ph~~ PF Bullet Level 28  8 q E~ "@@@@@@@B dd^ `d B*ph|| PF Bullet Level 35! 8 E~ "@@@@@@B8dd^8`d B*phn"n PF (Num) Level 3)" & F q E~ "@@@@@@Bd B*ph>/1> Style Bold5CJOJQJ\8PB8 r(- Body Text 2$dTR r(- Block TextB%$ nڏ05$7$8$9DH$]^`0a$!B*CJOJQJmH phsH tH ~Ob~ Ytab indent (double).&$ xdh^x`a$CJOJQJaJHrH & bodytext2'$^a$CJjj  Table Grid7:V(0(B' B Comment ReferenceCJaJ@@ + Comment Text *CJR/R *Comment Text CharOJQJ_HmH sH tH PK![Content_Types].xmlN0EH-J@%ǎǢ|ș$زULTB l,3;rØJB+$G]7O٭Vc:E3v@P~Ds |w< d 1  o('W"2##!)0 N !i!!!'"u""""#1### "#$%&'(*+,-./1}!@ @H 0(  0(  B S  ? _Toc57783935 _Toc57784768 _Toc71530924 _Toc57783936 _Toc57784769 _Toc71530925 _Toc61690928 _Toc71530926 _Toc3263603 _Toc47337675 _Toc57783938 _Toc57784771"111uu aaa999jejejeje>>MM9*urn:schemas-microsoft-com:office:smarttagsState9*urn:schemas-microsoft-com:office:smarttagsplace  35689;<>?P^ <BW^FI35689;<>?3333333333"&44:*+--fjEI?BVXuy   ^ _ e f n w ' ( H H >-.1((22223356689;<>?"&441((22223356689;<>?Ib t`Nʩ:C @G:H L@Rp#ҧHF)=L2:!tE?7A>AF^ABo3B+C-Fd>F&+IKJMaN)ONP-xRS4CS;vT:UeUUWxX ZZ.jZ)[5\a]^n^^UM`f{`eC/eL8e6i&L?&c#PQw@GL~.W&X-lX} E$eH ;]>N=5.o|Z=Lc W7uN'>`cVm"]8;2rKaa!7e &aH`H,*"5 wG@t?i/X.:~ 4A D:g~ 2RYF:N+$R2 )S0$_5hE`D&xo35@ {@Unknown G.[x Times New Roman5Symbol3. .Cx Arial;. .Cx HelveticaG^ Tempus Sans ITC5. .[`)TahomaS PalatinoBook Antiqua=& z Arial (W1)A$BCambria Math"1hbDGG $ 1$ 1!84&&2qHP?eU2!xx7 $Clinical Trial Preparation AgreementBSwartDimond, Siana (Health)4         Oh+'0 $0 P \ h t(Clinical Trial Preparation AgreementBSwart Normal.dotmDimond, Siana (Health)3Microsoft Office Word@G@į@b@$s$ ՜.+,0 hp  SA Pathology1 & %Clinical Trial Preparation Agreement Title  !"#$%&'()*+,-./012456789:<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdeghijklmopqrstuxRoot Entry FPszData 31Table;LTWordDocumentAdSummaryInformation(fDocumentSummaryInformation8nCompObjr  F Microsoft Word 97-2003 Document MSWordDocWord.Document.89q